MedTrace Logo

Effects of Genmont Probiotic on Improve the Level of Blood Glucose and Other Diabetic Associate Parameter in Type 2 Diabetes Patients

NCT02274272 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2017-10-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of probiotics ADR-1/GMNL-263 capsules (Lactobacillus reuteri ADR-1/ Lactobacillus reuteri GMNL-263) for the treatment of adults with type2 DM.

Conditions

Interventions

OTHER

ADR-1

two ADR-1 capsules, once daily, QD

OTHER

GMNL-263

two GMNL-263 capsules, once daily, QD

OTHER

placebo

two placebo capsules, once daily, QD

Sponsors & Collaborators

  • GenMont Biotech Incorporation

    lead INDUSTRY

Principal Investigators

  • yi shing Chen, PhD · GenMont Biothech Incorporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2017-04-30
Completion
2017-05-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02274272 on ClinicalTrials.gov